Solventum Corporation SOLV
89.50
0.91
1.03%
as of 25 Sep
- Market cap
- $15.1B
- P/E
- 10.9×
Follow SOLV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Solventum Corporation (SOLV) Debt to equity
Solventum Corporation's debt to equity at the end of the quarter to 30 June 2026 was 1.1×, up 0.1× from fiscal 2025 (1.0×). That is above the Medical Instruments & Supplies industry median of 0.1× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Annual
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 1.0× | (63.16%) |
| FY2024 | 2.7× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 1.1× | 3.51% |
| Mar 2026 | 1.1× | 6.70% |
| Dec 2025 | 1.0× | (3.21%) |
| Sep 2025 | 1.0× | (51.94%) |
| 11 more quarters | Free account |
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| ALGN Align Technology, Inc. compare | 0.0× |
| WST West Pharmaceutical Services, Inc. compare | 0.1× |
| ALC Alcon compare | 0.2× |
| RGEN Repligen Corporation compare | 0.3× |
| COO The Cooper Companies, Inc. compare | 0.3× |
| ATR AptarGroup, Inc. compare | 0.5× |
| AVTR Avantor, Inc. compare | 0.7× |
| SOLV Solventum Corporation | 1.1× |
| BAX Baxter International Inc. compare | 1.5× |
| Medical Instruments & Supplies industry median | 0.1× |
| Healthcare sector median | 0.0× |
| Market median | 0.2× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on SOLV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement